CD163 and metabolic dysfunction-associated steatotic liver disease: Figure 2 shows that sCD163 levels independently predicted MetS (OR: 5.35; 95% CI: 2.13~13.44, p < 0.001), NAFLD (OR: 2.19; 95% CI: 1.03~4.64, p < 0.05), and central obesity (OR: 3.90; 95% CI: 1.78~8.55, p < 0.001), after adjusting for age and sex.